VCA
AZN icon

Verdence Capital Advisors’s AstraZeneca AZN Stock Holding History

Verdence Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.14M Sell
15,937
-2,712
-15% -$523K 0.18% 121
2025
Q4 		$3.43M Sell
18,649
-2,102
-10% -$369K 0.2% 110
2025
Q3 		$3.49M Buy
20,751
+609
+3% +$92.2K 0.2% 120
2025
Q2 		$2.81M Buy
20,142
+491
+2% +$68.8K 0.19% 119
2025
Q1 		$2.89M Buy
19,651
+3,397
+21% +$491K 0.22% 110
2024
Q4 		$2.13M Buy
16,254
+1,503
+10% +$210K 0.17% 150
2024
Q3 		$2.3M Buy
14,751
+1,010
+7% +$163K 0.18% 143
2024
Q2 		$2.14M Buy
13,741
+5,069
+58% +$763K 0.19% 138
2024
Q1 		$1.18M Buy
8,672
+436
+5% +$57.7K 0.11% 216
2023
Q4 		$1.11M Sell
8,236
-549
-6% -$71.4K 0.11% 205
2023
Q3 		$1.19M Buy
8,785
+540
+7% +$73.8K 0.13% 183
2023
Q2 		$1.18M Sell
8,245
-1,017
-11% -$150K 0.14% 172
2023
Q1 		$1.29M Sell
9,262
-97
-1% -$13.1K 0.16% 159
2022
Q4 		$1.27M Buy
9,359
+641
+7% +$80.4K 0.16% 144
2022
Q3 		$956K Buy
8,718
+378
+5% +$48K 0.13% 173
2022
Q2 		$1.1M Buy
8,340
+1,398
+20% +$183K 0.14% 165
2022
Q1 		$921K Buy
6,942
+53
+0.8% +$6.36K 0.1% 208
2021
Q4 		$803K Buy
6,889
+805
+13% +$94.7K 0.09% 206
2021
Q3 		$731K Buy
6,084
+915
+18% +$107K 0.1% 214
2021
Q2 		$619K Sell
5,169
-37
-0.7% -$4.06K 0.09% 231
2021
Q1 		$518K Buy
5,206
+2,137
+70% +$215K 0.09% 218
2020
Q4 		$307K Buy
+3,069
New +$325K 0.06% 284
2019
Q1 		– Sell
-7,382
Closed -$561K – 272
2018
Q4 		$561K Sell
7,382
-2,254
-23% -$176K 0.16% 137
2018
Q3 		$763K Sell
9,636
-6,567
-41% -$497K 0.19% 120
2018
Q2 		$1.14M Sell
16,203
-2,246
-12% -$162K 0.28% 86
2018
Q1 		$1.29M Sell
18,449
-874
-5% -$60.5K 0.31% 76
2017
Q4 		$1.34M Buy
+19,323
New +$1.3M 0.32% 66

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Verdence Capital Advisors's AZN Position: Q1 2026 in Review

Verdence Capital Advisors reduced its AstraZeneca (AZN) stake by 15% in Q1 2026, selling an estimated $523K and leaving 15,937 shares worth $3.14M. The position accounts for 0.18% of the portfolio, ranked #121.

Verdence Capital Advisors first reported a position in AZN in Q4 2017 and has held it in 27 quarters since. The position peaked at $3.49M in Q3 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Verdence Capital Advisors held 15,937 shares of AstraZeneca worth $3.14M as of Q1 2026.
  • Verdence Capital Advisors sold 2,712 AstraZeneca shares in Q1 2026, an estimated $523K.
  • AstraZeneca made up 0.18% of Verdence Capital Advisors's portfolio in Q1 2026, its #121 holding.
  • Verdence Capital Advisors first reported a position in AstraZeneca in Q4 2017 and has held it in 27 quarters since.
  • Verdence Capital Advisors's AstraZeneca position peaked at $3.49M in Q3 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.